Category: Approval

March 16, 2022 Off

Lynparza Reduced Risk of Death by 32% in the Adjuvant Treatment of Patients with Germline BRCA-mutated High-risk Early Breast Cancer

By Dino Mustafić

Further positive results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy.